𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biodistribution, pharmacokinetics and imaging of 131I-labelled OC125 in ovarian cancer

✍ Scribed by Hidde J. Haisma; Karan R. Moseley; Anne I. Battaile; Thomas C. Griffiths; Vincent R. Zurawski; Robert C. Knapp

Publisher
John Wiley and Sons
Year
1988
Tongue
French
Weight
394 KB
Volume
41
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Fifteen patients with or suspected of having ovarian carcinoma were injected intravenously (i.v.) or intraperitoneally (i.p+) with t3tl-labelled OC 125 F(ab')z. Radioimmunoscintigraphy after i.v. injection revealed 50% of the tumor sites. After i.p. injection all tumor sites were visualized, except in one case in which the antibody remained loculated because of adhesions. One patient with endometrial cancer showed no specific uptake of the antibody after i.p. injection. The serum half-life of the radiolabelled antibody after i.v. injection was 30 hr. After i.p. injection there was a slow appearance of radiolabelled antibody in the blood with a maximum level of 1.4% dose per liter at 24 hr after injection. Urinary excretion of the radiolabel was the same for both routes of administration, with 50% of the dose excreted in approximately 48 hr. Tumor uptake was slightly higher after i.p. injection. Liver and bone marrow uptake after i.p. injection were one-half of the uptake after i.v. injection.

📜 SIMILAR VOLUMES

Pharmacokinetics, biodistribution and bi
Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients
✍ Jacoba G. Tibben; Otto C. Boerman; Leon F. A. G. Massuger; Charles P. T. Schijf; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 856 KB

The bispecific monoclonal antibody (biMAb) OC/TR combines the anti-ovarian-cancer reactivity of the MOvl8 monoclonal antibody (MAb) with the reactivity of an anti-CD3 MAb. Pre-clinical studies have indicated that this biMAb is able to redirect the cytolytic activity of T cells towards tumour cells,

Preparation and quality control of 211At
Preparation and quality control of 211At-labelled and 125I-labelled monoclonal antibodies. Biodistribution in mice carrying human osteosarcoma xenografts
✍ Roy H. Larsen; Per Hoff; Jorolf Alstad; Øyvind S. Bruland 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 439 KB

## Abstract Two anti‐osteosarcoma monoclonal antibodies (TP‐3 IgG and TP‐1 F(ab′)~2~) were labelled with the α‐particle emitting radionuclide ^211^At and, for comparison of stability, with ^125^I using the N‐succinimidyl‐3‐(trimethylstannyl)benzoate intermediate. The quality of the final preparatio

Biodistribution of 131I-labelled monoclo
Biodistribution of 131I-labelled monoclonal antibodies in human colon tumours by an ex vivo perfusion model
✍ E. Kraas; E. Löhde; O. Abri; H. Schlicker; S. Matzku; H. Kalthoff; W. Schmiegel; 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 French ⚖ 452 KB 👁 1 views

We describe a model for the evaluation of anti-tumour antibody specificity, using a human carcinoma-bearing colon segment. After resection of the human colon tumour, the supplying artery was cannulated and perfused with fresh frozen plasma and heparin. Continuous control of pressure, flow, temperatu

Biodistribution and pharmacokinetics of
Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma
✍ Adrián Chrastina; Jan Závada; Seppo Parkkila; Štefan Kaluz; Milota Kaluzová; Júl 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 417 KB

## Abstract Carbonic anhydrase IX (CA IX) is frequently expressed in human carcinomas and absent from the corresponding normal tissues. Strong induction by tumor hypoxia predisposes CA IX to serve as a target for cancer diagnostics and therapy. Here we evaluated targeting properties and pharmacokin

Therapeutic efficacy and dose-limiting t
Therapeutic efficacy and dose-limiting toxicity of auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model
✍ Thomas M. Behr; George Sgouros; Vassilios Vougioukas; Stavros Memtsoudis; Stefan 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 187 KB

Recent clinical results suggest that higher anti-tumor efficacy may be achieved with internalizing monoclonal antibodies (MAbs) at lower toxicity when labeled with Augerelectron, as compared to conventional ␤-emitters. The aim of our study was to compare the toxicity and anti-tumor efficacy of the 1

Distribution of radiolabelled anti-CA125
Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab′)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients
✍ Martina M. Uttenreuther-Fischer; Herbert Feistel; Friedrich Wolf; Wolfram Jäger 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Ovarian cancer is a highly malignant tumor of mainly postmenopausal women. The long-term prognosis of this malignancy is largely determined by micrometastasis present at the time of second-look surgery. In general, patients face a poor outcome. New radio-immunoscintigraphic methods to target tumor t